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Abstract
Background: Limb-girdle muscular dystrophy type 2C (LGMD2C) is an autosomal recessive muscle dystrophy that 
resembles Duchenne muscular dystrophy (DMD). Although DMD is known to affect one in every 3500 males regardless 
of race, a widespread founder mutation causing LGMD2C has been described in North Africa. However, the incidence 
of LGMD2C in Japanese has been unknown because the genetic background remains uncharacterized in many 
patients clinically diagnosed with DMD.
Methods: We enrolled 324 patients referred to the Kobe University Hospital with suspected DMD. Mutations in the 
dystrophin or the SGCG genes were analyzed using not only genomic DNA but also cDNA.
Results: In 322 of the 324 patients, responsible mutations in the dystrophin were successfully revealed, confirming 
DMD diagnosis. The remaining two patients had normal dystrophin expression but absence of γ-sarcoglycan in skeletal 
muscle. Mutation analysis of the SGCG gene revealed homozygous deletion of exon 6 in one patient, while the other 
had a novel single nucleotide insertion in exon 7 in one allele and deletion of exon 6 in the other allele. These 
mutations created a stop codon that led to a γ-sarcoglycan deficiency, and we therefore diagnosed these two patients 
as having LGMD2C. Thus, the relative incidence of LGMD2C among Japanese DMD-like patients can be calculated as 1 
in 161 patients suspected to have DMD (2 of 324 patients = 0.6%). Taking into consideration the DMD incidence for the 
overall population (1/3,500 males), the incidence of LGMD2C can be estimated as 1 per 560,000 or 1.8 per million.
Conclusions: To the best of our knowledge, this is the first study to demonstrate a low incidence of LGMD2C in the 
Japanese population.
Background
Duchenne muscular dystrophy (DMD; OMIM#310200) is
the most common inherited muscular dystrophy, and
affects 1 in every 3,500 males, regardless of race. DMD is
caused by a mutation in the dystrophin gene on the short
arm of the X chromosome and is characterized by the
absence of dystrophin in skeletal muscle. Those affected
by DMD develop muscle weakness by the age of 4 or 5,
followed by progressive muscle wasting that ultimately
leads to patients being wheelchair bound by the age of 12.
In addition, calf hypertrophy and lumbar lordosis are also
observed. DMD patients succumb to either cardiac or
respiratory failure secondary to the disease during their
twenties [1].
Limb-girdle muscular dystrophy type 2C (LGMD2C)
(OMIM # 253700) is an autosomal recessive disorder
caused by mutations in the SGCG gene, which encodes γ-
sarcoglycan. It is characterized by a childhood onset of
progressive muscular dystrophy. The mean age of onset is
5.3 years, and half of these patients lose ambulation by
the age of 12. Calf hypertrophy and lumbar lordosis are
common [2]. Based on these clinical findings, LGMD2C
is referred to as a severe childhood autosomal recessive
muscular dystrophy or as a Duchenne muscular dystro-
phy (DMD)-like autosomal recessive disease [3].
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Unlike DMD, LGMD2C shows geographical difference
in its incidence. The highest incidence of LGMD2C has
been reported in North Africa as a result of a founder
mutation in the SGCG gene [4]. Numerous studies have
summarized the clinical and pathological features of
LGMDs outside of North Africa. These studies have
reported at least 19 subtypes, with 7 exhibiting autosomal
dominant (LGMD1A to E) and 12 exhibiting autosomal
recessive (LGMD2A to J) patterns of inheritance [5]. Pre-
vious studies have determined the prevalence of LGMD
to range from 8.1 per million in a nationwide study in The
Netherlands [6] to 40 per million in a worldwide survey
[7]. However, the incidence of subtype LGMD2C has yet
to be determined. In the Bulgarian Roma (Gypsy) popula-
tion, one founder mutation has been reported to be com-
mon [8]. Other than in the geographical areas associated
with founder mutations, only limited numbers of
LGMD2C cases have been reported. For example, only
nine and seven LGMD2C patients have been described
among large numbers of patients examined in Italy [5]
and the USA [9], respectively.
Since differentiation of LGMD2C from DMD has not
been considered a major problem in current clinical prac-
tice, strong efforts to differentiate the two conditions
have not been made. Dystrophin restoration therapy for
DMD by either inducing exon skipping [10,11] or by sup-
pressing nonsense mutations [12] appears to be close to
clinical implementation. However, before there can be
any clinical application of these technologies, it is essen-
tial that DMD be confirmed at the molecular level.
Kobe University Hospital contains a DMD clinic that
examines patients suspected to have the disease from all
over Japan, especially from the western part of the coun-
try. We herein report on two LDMD2C patients that were
found among a group of 324 Japanese patients suspected
to have DMD. We accordingly estimate the incidence of
LGMD2C in the Japanese population to be 1 per 560,000.
Methods
Patients
Boys were enrolled in this cohort if they had been
referred to the Kobe University Hospital with a tentative
clinical DMD diagnosis based on strongly elevated levels
of serum creatine kinase (CK) activity. Patients ranged in
age from 0 - 7 years. We performed an extensive analysis
on mutations in the dystrophin gene and were able to
molecularly identify a mutation in the dystrophin gene in
322 patients with DMD-like disease (manuscript in prep-
aration). However, in two other patients, no mutations
were noted in the dystrophin gene. After obtaining
informed consent from their parents, further examina-
tions were conducted on these patients.
Methods
Muscle biopsy
Muscle samples were obtained from the quadriceps of
each patient. Standard histochemical stains including
hematoxylin and eosin (H-E), Gomori trichrome, NADH
tetrazolium reductase, succinate dehydrogenase, periodic
acid-Schiff, acid phosphatase, adenosine triphosphatase
at pH 4.3 and 9.4, cytochrome c oxidase, and alkaline
phosphatase were conducted. Immunohistochemical
stains for α- and β-dystroglycan; α-, β-, γ-, and δ-sarco-
glycan; dystrophin; and merosin were performed using
their respective monoclonal antibodies (Novocastra,
Newcastle upon Tyne, United Kingdom, and Millipore,
Billerica, MA, USA).
Gene analysis
Under an institutionally approved protocol, DNA was
extracted from blood samples that were obtained from
the probands and all available family members. For exam-
ination of the SGCG gene, eight sets of primers (Table 1)
were designed to amplify eight exons, with the amplified
PCR products then directly sequenced. Reverse tran-
scription PCR (RT-PCR) was used to analyze the SGCG
mRNA expressed in lymphocytes or skeletal muscle, as
previously described [13]. Full-length SGCG cDNA was
amplified as two separate, partially overlapping frag-
ments by using two sets of primers (Table 1). The ampli-
fied products were then directly sequenced.
Quantitative PCR
Genomic dosage of the exons of the SGCG gene was
assessed by a semiquantitative multiplex PCR, as previ-
ously described [14]. Eight fragments encompassing
exons 1 to 8 of the SGCG gene and one fragment encom-
passing exon 2 of the α-dystroglycan gene were co-ampli-
fied using two PCR reactions that employed six sets of
primers (Table 1). PCR products were separated by capil-
lary electrophoresis (Agilent 2001 Bioanalyzer with DNA
1000 Lab Chips, Agilent Technologies, Palo Alto, CA,
USA). The amount of PCR product derived from the
SGCG exons was quantified by measuring their peak
areas followed by calculating the ratio of these areas to
that found for the α-dystroglycan exon 2.
Results
The two male patients with clinical diagnosis of DMD
were incidentally found to have marked elevations of
serum CK levels (more than 50 times higher than control)
in early childhood, despite a negative family history for
muscular dystrophy. To confirm the clinical diagnosis of
DMD, dystrophin gene mutations were extensively
searched for using not only genomic DNA but also
mRNA. However, no mutations could be identified, even
when we included a deep intron mutation [15].
To clarify pathological changes in these two patients,
muscle biopsies were performed. In patient 1 (KUCGOkizuka et al. BMC Medical Genetics 2010, 11:49
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527), H-E staining revealed marked replacement of mus-
cle by adipose tissue along with increases in endomysial
connective tissue. We also found a few muscle fibers that
were remarkably different in size (data not shown). In
spite of the clinical diagnosis of DMD, the immunostain-
ing pattern for both dystrophin and merosin staining was
completely normal. Unexpectedly, there was no staining
for γ-sarcoglycan, while there was only a mild reduction
for α-sarcoglycan and almost normal results for β- and δ-
sarcoglycan (Figure 1). In order to confirm the γ-sarco-
glycan deficiency, we looked for mutations in the SGCG
gene. When PCR was used to amplify the eight exons that
encompassed the regions of the SGCG gene, all regions
other than exon 6 could be obtained. This suggests a
homozygous deletion of exon 6 (Figure 2). To confirm
this, we used RT-PCR to analyze the SGCG mRNA from
the patient's muscle. Amplification of the fragment
encompassing exons 5 to 8 resulted in a small-sized prod-
u ct.  S u bseq u e n t  s eq u e n ci n g  o f  t h is  p r od u ct  r ev e a l ed  a
complete absence of the exon 6 sequence (data not
shown). Therefore, we concluded that this patient had a
homozygous deletion of exon 6 in the SGCG gene. In
addition, both the patient's mother and father were found
to carry this deletion in one allele (data not shown).
Because the exon 6 deletion removes 73 bp (nt 506 - 578)
from the mRNA, it was expected that a stop codon would
appear in exon 7, thereby leading to γ-sarcoglycan defi-
ciency. It became clear that this patient had LGMD2C
rather than DMD.
In patient 2 (KUCG 280), H-E staining indicated excess
variability of muscle fiber size, clusters of regenerating
fibers, degenerating fibers, some acutely necrotic fibers,
and scattered inflammatory cells. Immunohistochemistry
revealed the absence of γ-sarcoglycan and a patchy
reduction in α- and β-sarcoglycan. The staining patterns
for dystrophin, δ-sarcoglycan, and merosin all appeared
normal (Figure 1). Since the findings suggested γ-sarco-
glycan deficiency, PCR amplification of the patient's
genomic DNA was performed for all eight exons in the
SGCG gene. Amplification of all fragments resulted in
products that were of the expected size, and thus, subse-
quently could be used for direct sequencing. With the
exception of exon 7, sequencing of the amplified products
demonstrated a completely normal sequence. In exon 7,
subcloning of an ambiguous sequence of the amplified
product resulted in one clone with a completely normal
sequence and a second clone that contained a novel single
T nucleotide insertion between nt 602 and 603 within
Table 1: Primer sequences
forward primer reverse primer
gSG 1F/R atgcgaagagctgtgtcctg tgccaccaaagaagaaagaa
gSG 2F/R gcctccctcattccctctct tcagagccagacagcaaagaa
gSG 3F/R ggagaaatgcagaaaaggtggt tgtgcacatgtatgcgcttt
gSG 4F/R cagcacctattttgcaaattttataaatc gcaccatgatgaagctggactc
gSG 5F/R tagggttgacgtggcatgtg tgtgtactccatggaatgttgtg
gSG 6F/R gcctgctaatttgtaattgctttg gcggaaagtcttgaaaataaagg
gSG 7F/R ttttgtgcttcttttcctcatctc cagtaggaggctgatctgtga
gSG 8F/R ccttaactcttcgtctcccatctt gcgtttacgtcccatccacgctgcc
gαDG 2F/R tccaactcggggtagatgtttt acttgaaaaggaaaagccacca
mSG 1F/7R cattctgtctgtggtagagctcgg gtttcagcatcaagcacaagcattcc
mSG 5F/8R aaatggtagaagtccagaatcaaca gcgtttacttcccatccacgctgcOkizuka et al. BMC Medical Genetics 2010, 11:49
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exon 7 (c.602_603insT). This mutation created a stop
codon in exon 7. The patient's mother was heterozygous
for this mutation, whereas the father had a normal exon 7
sequence (data not shown). Since patient 1 had a homolo-
gous deletion of exon 6 of the SGCG gene, we supposed
that patient 2 carried this deletion in one allele. When
semi-quantitative PCR amplification of exon 6 of the
patient's SGCG gene was performed, the results showed
nearly half the genomic dose for the exon 6 encompassing
region, indicating a heterozygous deletion of exon 6 (Fig-
ure 3). Further analysis of the SGCG mRNA from the
patient's muscle revealed two kinds of mRNA: one exhib-
ited an exon 6 deletion and the other demonstrated the
above-mentioned novel single nucleotide insertion
within exon 7 (Figure 3). Therefore, the γ-sarcoglycan
deficiency in this patient was caused by a hemizygous
c.602-603insT in exon 7 along with the deletion of exon 6
on the other allele.
To date, our analysis of patients suspected to have
DMD has revealed that two of the entire cohort examined
can be regarded as having LGMD2C. Thus, the relative
incidence of LGMD2C among Japanese patients sus-
pected to have DMD can be calculated as 1 in 161 (2 of
324 patients = 0.6%). When the DMD incidence is taken
into consideration for the overall population (1/3,500
males), the incidence of LGMD2C can be estimated as 1
per 560,000 or 1.8 per million.
Discussion
This is the first comprehensive study that has been able to
definitively clarify the incidence of LGMD2C among
patients suspected to have DMD. In our cohort of 324
Japanese children clinically diagnosed with DMD, two
were diagnosed as having LGMD2C. The incidence of
LGMD2C among this cohort was calculated as 1 in 161
(0.6%) and the incidence in the Japanese population was
estimated at 1 per 0.56 million people. The relative pro-
portions of all LGMDs, including LGMD2C, have been
previously reported for various regions of the world [5,9].
However, these reports did not describe the relative prev-
alence of LGMD2C to DMD. The present study is the
first to describe the incidence of LGMG2C in one race.
The incidence of severe LGMDs was estimated to be
11.8% in a German study of patients with severe muscular
dystrophy with early childhood onset [16] and about 8 to
12% in a Brazilian study of males with a clinical diagnosis
of DMD [17]. In comparison, our results indicate a much
Figure 1 Immunostaining of skeletal muscle. Results of immuno-
histochemical examination using dystrophin, α-, β-, γ-, and δ-sarcogly-
cans and dystrophin antibodies are shown. There was clear staining of 
every protein along the plasma membrane in the control. In patient 1, 
γ-sarcoglycan was completely absent, and there was a mild reduction 
of α-sarcoglycan. Both β-sarcoglycan and δ-sarcoglycan were found to 
be almost entirely intact. There was clear staining of dystrophin in pa-
tient 1. In patient 2, γ-sarcoglycan was completely absent, and a patchy 
reduction in both α- and β-sarcoglycan was observed. Dystrophin, δ-
sarcoglycan, and merosin staining patterns appeared normal.
Figure 2 Mutation analysis of the SGCG gene in patient 1. Amplifi-
cation products of exons 5, 6, and 7 are shown (c; control, p: patient) in 
the upper part of the figure. Although PCR amplification of eight exons 
of the SGCG gene was conducted, no products were obtained from 
the fragment encompassing exon 6 (Exon 6 p). For the other exons, the 
products of the SGCG gene met size expectations. Results of SGCG 
mRNA analysis are shown in the lower part of the figure. RT-PCR (c; 
control, p: patient) was used to analyze the muscle mRNA. The frag-
ment encompassing exons 5 to 8 was amplified as a small-sized prod-
uct in patient 1. Sequencing of the product showed a complete 
absence of exon 6. It was concluded that patient 1 had a homozygous 
deletion of exon 6 in the SGCG gene.Okizuka et al. BMC Medical Genetics 2010, 11:49
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lower incidence (0.6%) of LGMD2C among patients sus-
p e c t e d  t o  h a v e  D M D .  H o w ev e r ,  t h e  l o w  p r ev a l e n c e  o f
L G M D 2 C  i n  J a p a n e s e  i s  i n  a c c o r d a n c e  w i t h  t h e  f e w
r e p o r t s  t h a t  h a v e  e x a m i n e d  L C M D 2 C  p a t i e n t s  f r o m
Japan [18,19]. Regardless of these differences, the poten-
tial presence of LGMD2C needs to be considered when
making a differential diagnosis of DMD, even in Japan.
Although originally reported to be a severe autosomal
recessive muscular dystrophy that resembles DMD,
LGMD2C has since been reported to have a heteroge-
nous clinical course, even with identical mutations [19].
Initially, both of our LGMD2C patients were tentatively
diagnosed as having DMD, even though both patients
showed only very mild muscle weakness during the origi-
nal observation period. A clinical hallmark for differenti-
ating DMD and LGMD2C involves the inheritance
pattern. However, this is impossible to determine in spo-
radic cases in males. In the current cases, the failure to
determine any dystrophin gene mutations that were
responsible for DMD led to immunohistochemical exam-
ination of muscle tissue. Quite unexpectedly, we found
normal staining for dystrophin in these patients (Figure
1). This finding proved to be the key for diagnosing the
complete or near-complete absence of γ-sarcoglycan defi-
ciency, which led to our using genetic analysis to defini-
tively prove the γ-sarcoglycan deficiency.
It has been reported that residual sarcoglycan expres-
sion is highly variable, and that this makes it difficult to
accurately predict the genotype [2,20]. In addition, both
sarcoglycanopathy and DMD were reported to show
weak staining of all types of sarcoglycan complexes [20].
On the other hand, patients with LGMD2C have been
reported to show a significant reduction or a complete
absence of γ-sarcoglycan staining in conjunction with
reduced or only partially preserved staining of the other
sarcoglycan proteins [2,5,9,21,22]. In the present two
cases, we observed a marked reduction of γ-sarcoglycan,
in addition to finding a reduction of staining intensity for
other members of the sarcoglycan complex (Figure 1).
Since the maintenance of the carboxyl terminus of γ-
sarcoglycan is important for both the processing and sta-
bility of the protein, mutations in the extracellular
domain of γ-sarcoglycan can lead to an absence of protein
expression [4]. While the most common cause of
LGMD2C is thought to be a homozygous del521T in exon
6 of the SGCG gene, this mutation has not been reported
in Japanese. However, in the current study we identified a
novel c.602_603insT mutation. We identified a homozy-
gous deletion of exon 6 of the SGCG gene in patient 1.
We also identified the exon 6 deletion in three of four
alleles in our two Japanese LGMD2C patients. This muta-
tion has been previously reported to occur as a hemizy-
gous condition in Japanese [19]. In Europe, this exon 6
d e l e t i o n  h a s  b e e n  r e p o r t e d  i n  b o t h  h o m o z y g o u s  a n d
hemizygous conditions [23]. Taken together, these previ-
ous findings suggest that exon 6 can be considered prone
to deletions. Although our identification of the exon 6
deletion in one allele was initially difficult, we have now
been able to successfully detect deletions in one allele by
using semiquantitative PCR amplification (Figure 3).
Therefore, use of this methodology may help to increase
the mutation detection rate in patients suspected to have
DMD, and in addition, help to correctly identify
LGMD2C. Being able to successfully identify LGMD2C
patients in the future will help to ensure correct DMD
diagnosis and proper implementation of therapy in
patients who do indeed have DMD.
Conclusion
This is the first comprehensive study to describe the
prevalence of LGMD2C in one race from mutation study
results on patients suspected to have DMD. The inci-
dence of LGMD2C in the Japanese population was esti-
mated to be 1 per 560,000.
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Figure 3 Mutation analysis of the SGCG gene in patient 2. Capillary 
electrophoretic patterns of the PCR products are shown in the upper 
portion of the figure. Five genomic regions were co-amplified in one 
PCR reaction, with the products separated using capillary electropho-
resis. The position of each of the amplified products of exons 5, 6, 7, 
and 8 of the SGCG gene and exon 2 of the α-dystroglycan gene (DG) 
are marked. In patient 2, the peak area of exon 6 is nearly half that of 
the control, indicating a heterozygous deletion of exon 6. IS refers to a 
1,500-bp marker. The amplified fragments that encompassed exons 5 
to 8 of the SGCG mRNA are shown in the lower part of the figure (c; 
control, p; patient). Two different product sizes were obtained from the 
patient. Sequencing of the products disclosed that one exhibited a 
complete absence of exon 6, while the other included a nucleotide in-
sertion in exon 7 (c.602_603insT). Thus, in this patient there was both a 
heterozygous nucleotide insertion in exon 7 and a heterozygous dele-
tion of exon 6 of the SGCG gene.Okizuka et al. BMC Medical Genetics 2010, 11:49
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